VENLAFAXINE TREATMENT OF ATYPICAL DEPRESSIONS IN PERIMENOPAUSAL WOMEN: A PILOT STUDY
In a pilot study of venlafaxine therapy in atypical depressions co- morbid with menopausal syndrome, satisfactory efficacy of venlafaxine 37,5- 225 mg daily was observed. Some predictors of atypical depressions in perimenopausal women, including minimal brain dysfunction, anankast personality and prolonged, inescapable distress, were revealed. Asthenic, dysphoric, depressive and anxious symptoms significantly reduced during venlafaxine therapy. Pilot studies of venlafaxine treatment in other cohorts of patients with atypical depressions can also be perspective.